



# $^1\text{H}$ , $^{13}\text{C}$ , $^{15}\text{N}$ backbone and side-chain resonance assignments of the pathogenic G131V mutant of human prion protein (91–231)

Qiaodong Zhang<sup>1</sup> · Haoran Zhang<sup>1</sup> · Fengyu Zheng<sup>1</sup> · Rong Liu<sup>1</sup> · Xinli Liao<sup>1</sup> · Chenyun Guo<sup>1</sup> · Donghai Lin<sup>1</sup>

Received: 21 February 2021 / Accepted: 8 April 2021 / Published online: 19 April 2021  
© The Author(s), under exclusive licence to Springer Nature B.V. 2021

## Abstract

Human prion disease, also known as transmissible spongiform encephalopathy (TSEs), is caused by the conformational conversion of the normal cellular prion protein (PrP<sup>C</sup>) into the scrapie form (PrP<sup>Sc</sup>). Pathogenic point mutations of prion proteins typically facilitate conformational conversion and lead to inherited prion diseases. A previous study has demonstrated that the pathogenic G131V mutation of human prion protein (HuPrP) brings in Gerstmann–Sträussler–Scheinker syndrome. However, the three-dimensional structure and dynamic features of the HuPrP(G131V) mutant remain unclear. It is expected that the determination of these structural bases will be beneficial to the pathogenic mechanistic understanding of G131V-related prion diseases. Here, we performed  $^1\text{H}$ ,  $^{15}\text{N}$ ,  $^{13}\text{C}$  backbone and side-chain resonance assignments of the G131V mutant of HuPrP(91–231) by using heteronuclear multi-dimensional NMR spectroscopy, and predicted the secondary structural elements and order parameters of the protein based on the assigned backbone chemical shifts. Our work lays the necessary foundation for further structural determination, dynamics characterization, and intermolecular interaction assay for the G131V mutant.

**Keywords** Human prion protein · Pathogenic mutation G131V · NMR resonance assignments · Secondary structure prediction

## Biological context

Prion disease, the notorious transmissible spongiform encephalopathy (TSEs), is a kind of fatal neurodegenerative illness related to the central nervous system (Prusiner 1998). Four kinds of prion diseases have been identified in humans including fatal familial insomnia (FFI), Kuru, Gerstmann–Sträussler–Scheinker syndrome (GSS), and Creutzfeldt–Jakob disease (CJD) (Tee et al. 2018). These diseases result from the conformational conversion of the normal cellular prion protein (PrP<sup>C</sup>) into the scrapie isoform

prion protein (PrP<sup>Sc</sup>) (Prusiner 1982; Rayman and Kandel 2017). Interestingly, PrP<sup>C</sup> is mainly  $\alpha$ -helix-rich, whereas PrP<sup>Sc</sup> is  $\beta$ -sheet-rich (Pan et al. 1993).

The wild-type human prion protein (WT HuPrP) is composed of 230 amino acid residues, including an N-terminal random coil (residues 23–124) and a C-terminal globular domain (residues 125–231) associated with many pathogenic and protective mutations (Beck et al. 2010; Giachin et al. 2013). Pathogenic point mutations of human prion proteins were reported to accelerate conformational conversions and cause inherited prion diseases (Beck et al. 2010). For the M129 RPNP allele of HuPrP, the G127V mutation causes complete resistance to prion diseases (Mead et al. 2009; Asante et al. 2015), while the G131V mutation leads to the Gerstmann–Sträussler–Scheinker (GSS) disease (Panegyres et al. 2001).

The three-dimensional (3D) structure of the C-terminal domain of WT HuPrP(91–231) in solution has been determined by using heteronuclear multi-dimensional NMR spectroscopy, which is comprised of three  $\alpha$ -helices ( $\alpha$ 1: 144–154,  $\alpha$ 2: 173–194,  $\alpha$ 3: 200–228), a short  $\beta$ -sheet ( $\beta$ 1: 128–131,  $\beta$ 2: 161–164) and a disulfide bridge (Cys179–Cys214) (Zahn

Qiaodong Zhang and Haoran Zhang have contributed equally to this work.

✉ Chenyun Guo  
guochy78@xmu.edu.cn

✉ Donghai Lin  
dhlin@xmu.edu.cn

<sup>1</sup> High-field NMR center, Key Laboratory of Chemical Biology of Fujian Province, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen 361005, China

et al. 2000). The 3D structure of WT HuPrP shows that the residue G131 is located in the  $\beta$ 1-strand. Previously, we determined the 3D structure of the disease-resistant HuPrP(G127V) mutant spanning 91–231 in solution with NMR techniques, and indicated that HuPrP(G127V) consists of the  $\alpha$ 1,  $\alpha$ 2 and  $\alpha$ 3 helices and a stretch-strand (SS) pattern with two fragments (SS1: 128–131, SS2: 161–164) rather than the  $\beta$ -sheet contained in the WT protein (Zheng et al. 2018). Our previous work revealed that HuPrP(G127V) prevents formations of stable  $\beta$ -sheets and dimers through performing molecular dynamics simulations (Zheng et al. 2018). Notably, G131 is located in the SS1 fragment. Moreover, we carried out NMR dynamics analyses of HuPrP(G127V) and WT HuPrP, indicating that Gly131 underwent significant conformational exchange only in HuPrP(G127V) (Zheng et al. 2018). Furthermore, we found that the G131V mutation alleviates the fibrillization but promotes the oligomerization of HuPrP(91–231), suggesting that the oligomerization might play a vital role in the pathogenic mechanisms of the G131V mutant. We also exhibited that the flexible N-terminal fragment in both HuPrP(G127V) and WT HuPrP decreases fibrillization tendencies but increases oligomerization tendencies (Zhang et al. 2019).

Additionally, Santini et al. performed molecular dynamics simulations and showed that the G131V mutation enhances the flexibility of residues participating in the two-step process for prion propagation at neutral pH (Santini et al. 2003). Furthermore, we observed profound differences in 2D  $^1\text{H}$ - $^{15}\text{N}$  HSQC spectra between HuPrP<sup>C</sup>(G131V) and WT HuPrP<sup>C</sup> proteins, which implied that the G131 mutation induced significant conformational changes in HuPrP. Expectedly, the conformational distinctions between the two proteins potentially contribute to the pathogenesis of G131V-related prion diseases. However, the conformational distinctions remain unclear due to the lack of three-dimensional (3D) structure of HuPrP(G131V) until now.

In the present study, we performed  $^1\text{H}$ ,  $^{13}\text{C}$ ,  $^{15}\text{N}$  backbone and side-chain resonance assignments of the G131V mutant of HuPrP(91–231) spanning 91–231 by using heteronuclear multi-dimensional NMR spectroscopy, and predicted the secondary structures and order parameters of the protein based on the backbone resonance chemical shifts with the TALOS-N program. Our results lay the basis for further structural determination and NMR dynamics characterization as well as intermolecular interaction assay for the pathogenic HuPrP(G131V) mutant.

## Methods and experiments

### Plasmid construction, protein expression and purification

A recombinant of the pET30a plasmid bearing the DNA of the WT HuPrP (residues 91–231 with the G131M129 genotype) was used as a template plasmid (Wen et al. 2010a, b). A single point mutant on this plasmid containing a valine substitution of glycine 131 (G131V) was constructed via site-directed mutagenesis PCR and transformed into the *E. coli* BL21(DE3) strain. The uniformly  $^{13}\text{C}/^{15}\text{N}$ -labeled proteins were overexpressed at 37 °C in the M9 medium, to which both 1 g/L  $^{15}\text{NH}_4\text{Cl}$  and 3 g/L  $^{13}\text{C}$ -glucose were added. The expression of HuPrP(G131V) protein was induced at  $\text{OD}_{600\text{nm}} = 0.8$ –1.2 using 1 mM isopropyl- $\beta$ -D-thiogalactopyranoside for 4–5 h at 37 °C. Cells were harvested by centrifugation and later resuspended in lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, 0.1% Triton X-100, pH 7.4), followed by the addition of PMSF (20  $\mu\text{g}/\text{mL}$ ) with subsequent sonication on ice for 35 min. After centrifugation at 11,000 rpm for 40 min at 4 °C to pellet down the cell debris, the sediment was dissolved in buffer B<sub>1</sub> (20 mM Tris-HCl, 150 mM NaCl, 0.5% Triton X-100, pH 7.4), stirred for 1 h at 4 °C, and centrifuged at 11,000 rpm for 30 min at 4 °C. This step was repeated sequentially in buffer B<sub>2</sub> (20 mM Tris-HCl, 2 M NaCl, pH 7.4) and buffer B<sub>3</sub> (20 mM Tris-HCl, 150 mM NaCl, 2 M Urea, pH 7.4). To denature the protein, the resulting pellet was dissolved in buffer C (10 mM Tris-HCl, 100 mM  $\text{Na}_2\text{HPO}_4$ , 6 M GdnHCl, 0.5% Triton X-100, 10 mM  $\beta$ -mercaptoethanol, pH 8.0). Then, the denatured protein was stepwise dialyzed and refolded against buffer D (10 mM Tris-HCl, 100 mM  $\text{Na}_2\text{HPO}_4$ , pH 8.0) in a concentration gradient. The refolded HuPrP<sup>C</sup>(G131V) protein was further purified by size exclusion chromatography (SEC) with Superdex 75 column attached to an AKTA fast protein liquid chromatography system (GE Healthcare, Wisconsin, USA) pre-equilibrated with buffer F (20 mM NaAc, 0.02%  $\text{NaN}_3$ , pH 4.5). Finally, the protein solutions were concentrated to approximately 0.65 mM in NMR buffer (20 mM NaAc, 0.02%  $\text{NaN}_3$ , 10%  $\text{D}_2\text{O}$ , pH 4.5).

### NMR spectroscopy

To perform backbone and side-chain resonance assignments of the HuPrP<sup>C</sup>(G131V) protein, a suite of heteronuclear 2D/3D NMR spectra were recorded at 298 K on a Bruker Avance III 850-MHz spectrometer with a  $^1\text{H}/^{13}\text{C}/^{15}\text{N}$  triple-resonance cryogenic probe (TCI). The

2D NMR spectra included  $^1\text{H}$ - $^{13}\text{C}$  HSQC and  $^1\text{H}$ - $^{15}\text{N}$  HSQC. The 3D NMR spectra covered HNCACB, HNCA, HN(CA)CO, CBCA(CO)NH, HN(CO)CA, HCCH-TOCSY, HNCO, HBHA(CO)NH, H(CCCO)NH, CC(CO)NH, CCH-TOCSY, and  $^{15}\text{N}$ -edited TOCSY-HSQC using non-uniform sampling (NUS) with a sampling rate of 25%. Furthermore, both 3D  $^{15}\text{N}$ -edited NOESY-HSQC and  $^{13}\text{C}$ -edited NOESY-HSQC spectra were recorded using traditional uniform sampling with a mixing time of 100 ms.


All NMR spectra were acquired with the Bruker TopSpin 3.6.2 software, processed with the NMRPipe software (Delaglio et al. 1995) and analyzed with the Sparky software (Lee et al. 2015). All the 3D spectra recorded with non-uniform sampling were reconstructed and processed by using the SMILE package of NMRPipe (Ying et al. 2017). Both the secondary structures and order parameters of HuPrP<sup>C</sup>(G131V) were predicted based on the assigned backbone chemical shifts using the TALOS-N program (Shen and Bax 2013).

### Assignment and data deposition


The recombinantly expressed HuPrP<sup>C</sup>(G131V) protein consists of 141 amino acid residues (residues 91–231) with 5 proline residues (102, 105, 137, 158 and 165). Superimposition of the 2D  $^1\text{H}$ - $^{15}\text{N}$  HSQC spectra of HuPrP<sup>C</sup>(G131V) and WT HuPrP<sup>C</sup> indicates that the G131V mutation induced significant structural changes in the protein (Fig. 1). Backbone and side-chain resonances

of the G131V mutant were assigned based on the recorded heteronuclear 2D/3D NMR spectra (Fig. 2). In total, 89.7% of the  $^1\text{H}^{\text{N}}$  and  $^{15}\text{N}$  resonances of all non-proline residues were unambiguously assigned. In detail, 93.6% of  $^{13}\text{C}_{\alpha}$  (132 of 141), 92.2% of  $^{13}\text{C}_{\beta}$  (119 of 129), 92.2% of  $^{13}\text{C}(\text{O})$  (130 of 141), 93.9% of  $^1\text{H}_{\alpha}$  (155 of 165), and 80.68% of side-chain  $^1\text{H}$  resonances have been assigned. Some residues (Met129-Ser132, Val161, Tyr162, Asp167-Asn171, Phe175, Ile182 and Gln217) had no available resonance assignments for backbone amide groups. Among these residues, however, Ser132, Tyr162, Asn171, Phe175, Ile182 and Gln217 had available resonance assignments for  $^{13}\text{C}_{\alpha}$ ,  $^{13}\text{C}_{\beta}$ ,  $^{13}\text{C}(\text{O})$ ,  $^1\text{H}_{\alpha}$  atoms.

The solution structure of WT HuPrP(91–231) (Zheng et al. 2018; PDB: 5YJ5) contains two short  $\beta$ -strands ( $\beta$ 1: 128–131,  $\beta$ 2: 161–164). Backbone amide resonances of M129, I130, and V131 were visible in the HSQC spectrum of the WT protein, but invisible in that of the G131V mutant. The spectral differences suggested that the G131V mutation induced significant conformational changes in the  $\beta$ -sheet of the prion protein. The superimposed  $^1\text{H}$ - $^{15}\text{N}$  HSQC spectra of the G131V mutant and WT protein spanning 91–231 illustrate that the G131V mutation induced peak broadening for residues including Ala133, Ile215, Tyr218 and Arg220, and even peak disappearing for four residues (Met129, Ile130, Val161 and Gln217). The assigned chemical shifts of the backbone and side-chain atoms in HuPrP<sup>C</sup>(G131V) have been deposited in BioMagResBank (<http://www.bmrb.wisc.edu/>) under the access number 50,544.



**Fig. 1** Superimposed  $^1\text{H}$ - $^{15}\text{N}$  HSQC spectra of WT HuPrP (91–231) and HuPrP<sup>C</sup>(G131V) proteins spanning 91–231. The spectra were recorded at 298 K on a Bruker Avance III 850-MHz spectrometer in NMR buffer (20 mM NaAc, 0.02%  $\text{NaN}_3$ , 10%  $\text{D}_2\text{O}$ , pH 4.5)



**Fig. 2** 2D  $^1\text{H}$ - $^{15}\text{N}$ -HSQC spectrum of the HuPrP<sup>C</sup>(G131V) protein spanning 91–231. Peaks are labeled with residues names in one-letter code and sequence numbers


Using the TALOS-N server (<https://spin.niddk.nih.gov/bax/software/TALOS-N/>), we predicted the secondary structure elements of HuPrP<sup>C</sup>(G131V) spanning 91–231 based on the assigned chemical shifts of the backbone  $\text{H}^{\text{N}}$ ,  $\text{H}_{\alpha}$ ,  $\text{C}_{\alpha}$ ,  $\text{C}_{\beta}$ ,  $\text{C}(\text{O})$  and  $\text{N}$  (Fig. 3a). The prediction results suggested that the solution structure of the G131V mutant contained three  $\alpha$ -helices ( $\alpha 1$ : 144–153,  $\alpha 2$ : 172–192,  $\alpha 3$ : 200–226) (Fig. 3a). The predicted helices in HuPrP<sup>C</sup>(G131V) were consistent with the experimentally determined helices in WT HuPrP<sup>C</sup>(144–154, 173–194, 200–228) (Zahn et al. 2000). Residues 161–164 were predicted to be a  $\beta$ -strand. Note that residues 128–131 form a  $\beta$ -strand comprising a  $\beta$ -sheet with another  $\beta$ -strand (residues 161–164) in WT HuPrP(91–231). In HuPrP(G131V), however, residues 128–131 were not predicted to be a  $\beta$ -strand due to unavailable resonance assignments of backbone amide groups for M129–S132 as described above. Whether the residues 161–164 could form a  $\beta$ -strand in HuPrP(G131V) need to be clarified by the 3D structure of HuPrP(G131V) determined in near future.

Apart from the prediction on this fragment, the prediction of secondary structures was generally reliable. Additionally, we used the TALOS-N program to predict random coil index (RCI) order parameters ( $S^2$ ) for the residues with assigned backbone chemical shifts (Fig. 3b). As is known, residues with  $S^2$  value  $< 0.7$  are generally located in flexible

fragments, while those with  $S^2$  value  $> 0.7$  are typically associated with the rigid conformation. Thus, we used a cut-off of 0.7 to distinguish rigid and flexible backbone atoms. Similar to WT HuPrP, the fragment Gln91–Gly127 and the C-terminus showed evidence of conformational flexibility. Notably, the predicted  $\beta 1$  exhibited high  $S^2$  values comparable to the three  $\alpha$ -helices. As the G131V mutation might affect the conformational stability of the  $\beta$ -sheet, the large  $S^2$  values of the fragment 161–164 could also result from the stabilization of their side chains by spatially neighboring residues in the helices. As an illustration, the fragment 161–164 in WT HuPrP(91–231) is stabilized by not only the hydrogen bonds with residues 128–131, but also hydrophobic interactions with non-polar residues like Phe175, Val210 and Met213 (PDB: 5YJ5). To conclude, the differences in the secondary structures between HuPrP(G131V) and WT HuPrP might contribute to the pathogenesis of G131V-related prion diseases.

In summary, we have performed  $^1\text{H}$ ,  $^{13}\text{C}$ ,  $^{15}\text{N}$  backbone and side-chain resonance assignments of HuPrP<sup>C</sup>(G131V) spanning 91–231 and predicted the secondary structural elements and order parameters of the prion protein. The G131V mutation significantly changes the conformation of the human prion protein. This work lays the basis for the further structural and dynamics studies of

**Fig. 3** Secondary structures and order parameters of HuPrP<sup>C</sup>(G131V) spanning 91–231 predicted from the assigned backbone chemical shifts. **a** Secondary structural elements of HuPrP(G131V) were predicted based on backbone chemical shifts by using the TALOS-N program with a propensity cutoff of 0.5. **b** Random coil index (RCI) order parameters ( $S^2$ ) were calculated from secondary chemical shifts for individual residues by TALOS-N. A cutoff of 0.7 was used for distinguishing rigid and flexible backbone atoms



HuPrP<sup>C</sup>(G131V), and may be beneficial to an understanding of molecular mechanisms underlying the conformational conversion associated with the pathogenic G131V mutation.

**Acknowledgements** This work was supported by grants from the National Science Foundation of China (No. 31670741), the National Key Research and Development Project of China (No. 2016YFA0500600)

and the Foundation for Innovative Research Groups of the National Natural Science Foundation of China (No. 21521004).

## Declarations

**Conflict of interest** The authors declare that there is no conflict of interest.



## References

- Asante EA et al (2015) A naturally occurring variant of the human prion protein completely prevents prion disease. *Nature* 522(7557):478–478
- Beck JA et al (2010) PRNP allelic series from 19 years of prion protein gene sequencing at the MRC prion unit. *Hum Mutat* 31(7):E1551–E1563
- Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A (1995) NMRPipe: a multidimensional spectral processing system based on UNIX pipes. *J Biomol NMR* 6(3):277–293
- Giachin G, Biljan I, Ilc G, Plavec J, Legname G (2013) Probing early misfolding events in prion protein mutants by NMR spectroscopy. *Molecules* 18(8):9451–9476
- Lee W, Tonelli M, Markley JL (2015) NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy. *Bioinformatics* 31(8):1325–1327
- Mead S et al (2009) A novel protective prion protein variant that colocalizes with kuru exposure. *New Engl J Med* 361(21):2056–2065
- Pan KM et al (1993) Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. *Proc Natl Acad Sci USA* 90(23):10962–10966
- Panegyres PK et al (2001) A new PRNP mutation (G131V) associated with Gerstmann-Straussler-Scheinker disease. *Arch Neurol* 58(11):1899–1902
- Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. *Science* 216(4542):136–144
- Prusiner SB (1998) Prions. *Proc Natl Acad Sci USA* 95(23):13363–13383
- Rayman JB, Kandel ER (2017) Functional prions in the brain. *Cold Spring Harb Perspect Biol* 9(1):a023671
- Santini S, Claude JB, Audic S, Derreumaux P (2003) Impact of the tail and mutations G131V and M129V on prion protein flexibility. *Proteins Struct Funct Bioinform* 51(2):258–265
- Shen Y, Bax A (2013) Protein backbone and sidechain torsion angles predicted from NMR chemical shifts using artificial neural networks. *J Biomol NMR* 56:227–241. <https://doi.org/10.1007/s10858-013-9741-y>
- Tee BL, Longoria Ibarrola EM, Geschwind MD (2018) Prion diseases. *Neurol Clin* 36(4):865–897
- Wen Y et al (2010a) Solution structure and dynamics of the I214V mutant of the rabbit prion protein. *PLoS ONE* 5(10):e13273
- Wen Y et al (2010b) Unique structural characteristics of the rabbit prion protein. *J Biol Chem* 285(41):31682–31693
- Ying JF, Delaglio F, Torchia DA, Bax A (2017) Sparse multidimensional iterative lineshape-enhanced (SMILE) reconstruction of both non-uniformly sampled and conventional NMR data. *J Biomol Nmr* 68(2):101–118
- Zahn R et al (2000) NMR solution structure of the human prion protein. *Proc Natl Acad Sci USA* 97(1):145–150
- Zhang M et al (2019) Biophysical characterization of oligomerization and fibrillization of the G131V pathogenic mutant of human prion protein. *Acta Biochim Biophys Sin (Shanghai)* 51(12):1223–1232
- Zheng Z et al (2018) Structural basis for the complete resistance of the human prion protein mutant G127V to prion disease. *Sci Rep* 8(1):13211

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.